Published in Virol J on August 01, 2011
Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus. Arch Virol (2013) 0.90
Characterization of HIV-1 infection and innate sensing in different types of primary human monocyte-derived macrophages. Mediators Inflamm (2013) 0.80
Abrogation of contaminating RNA activity in HIV-1 Gag VLPs. Virol J (2011) 0.77
Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther (2000) 12.54
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25
Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods (2008) 1.74
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology (2007) 1.74
Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci U S A (1997) 1.53
Toward an antibody-based HIV-1 vaccine. Annu Rev Med (2010) 1.45
A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell (2006) 1.38
Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS (2009) 1.36
Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1990) 1.30
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology (2006) 1.10
Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol (2005) 1.05
The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell Immunol (1997) 0.98
Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine (2009) 0.98
Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res Hum Retroviruses (2001) 0.98
Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine (2007) 0.92
Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS (2007) 0.91
DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine (2009) 0.90
Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology (2007) 0.79
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci U S A (2013) 1.69
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis (2010) 1.52
Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol (2006) 1.52
Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol (2004) 1.48
Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res (2003) 1.47
Innate immune recognition and activation during HIV infection. Retrovirology (2010) 1.45
Focal complex maturation and bridging on 200 nm vitronectin but not fibronectin patches reveal different mechanisms of focal adhesion formation. Nano Lett (2011) 1.42
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial. Vasc Endovascular Surg (2009) 1.39
Proteasomal degradation of herpes simplex virus capsids in macrophages releases DNA to the cytosol for recognition by DNA sensors. J Immunol (2013) 1.38
Characterization of the TRBP domain required for dicer interaction and function in RNA interference. BMC Mol Biol (2009) 1.37
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS (2006) 1.33
RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1. J Biol Chem (2009) 1.30
Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS One (2012) 1.30
Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open (2013) 1.29
Tackling drought stress: receptor-like kinases present new approaches. Plant Cell (2012) 1.23
The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1. PLoS One (2011) 1.17
Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response. J Virol (2005) 1.17
Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient. Clin Infect Dis (2008) 1.16
Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis (2008) 1.14
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology (2002) 1.12
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One (2012) 1.12
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Cytosolic RNA recognition pathway activates 14-3-3 protein mediated signaling and caspase-dependent disruption of cytokeratin network in human keratinocytes. J Proteome Res (2010) 1.11
Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol (2007) 1.07
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis (2011) 1.05
The use of combinatorial topographical libraries for the screening of enhanced osteogenic expression and mineralization. Biomaterials (2009) 1.05
Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol (2006) 1.04
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology (2008) 1.04
Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J Virol (2010) 1.04
Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine (2005) 1.04
Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages. J Virol (2002) 1.02
Shielding of sleeping beauty DNA transposon-delivered transgene cassettes by heterologous insulators in early embryonal cells. Mol Ther (2008) 1.02
Identification of distinct topographical surface microstructures favoring either undifferentiated expansion or differentiation of murine embryonic stem cells. Stem Cells Dev (2009) 1.02
A minimal uORF within the HIV-1 vpu leader allows efficient translation initiation at the downstream env AUG. Virology (2007) 1.02
Suppression of proinflammatory cytokine expression by herpes simplex virus type 1. J Virol (2004) 0.99
Gender differences in hospitalization rates for respiratory tract infections in Danish youth. Scand J Infect Dis (2004) 0.98
Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine (2009) 0.98
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis (2012) 0.97
Septin9 is involved in septin filament formation and cellular stability. Biol Chem (2011) 0.96
Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr (2011) 0.96
Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol (2002) 0.96
Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression. J Immunol (2013) 0.95
Meristematic sculpting in fruit development. J Exp Bot (2009) 0.95
Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biol (2011) 0.94
Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals. PLoS One (2011) 0.93
Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs. J Virol (2007) 0.93
Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma (2009) 0.93
Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. PLoS One (2013) 0.92
Cellular uptake and membrane-destabilising properties of alpha-peptide/beta-peptoid chimeras: lessons for the design of new cell-penetrating peptides. Biochim Biophys Acta (2008) 0.91
Broad-range real time PCR and DNA sequencing for the diagnosis of bacterial meningitis. Scand J Infect Dis (2006) 0.91
Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS (2007) 0.91
Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study. PLoS One (2013) 0.91
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine (2004) 0.90
Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One (2011) 0.90
Change of tropism of SL3-2 murine leukemia virus, using random mutational libraries. J Virol (2004) 0.90
Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: a Danish historical cohort study. BMC Infect Dis (2010) 0.89
Complexity of the inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant virus and outcome of infection. PLoS Pathog (2009) 0.89
Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation (2005) 0.88
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis (2011) 0.88
Crowding as a risk factor of meningococcal disease in Danish preschool children: a nationwide population-based case-control study. Scand J Infect Dis (2004) 0.88
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One (2013) 0.88
Absence of xenotropic murine leukaemia virus-related virus in Danish patients with multiple sclerosis. J Clin Virol (2010) 0.88
Monitoring cell adhesion on tantalum and oxidised polystyrene using a quartz crystal microbalance with dissipation. Biomaterials (2006) 0.87
Experiences from a randomised, controlled trial on cycling to school: does cycling increase cardiorespiratory fitness? Scand J Public Health (2012) 0.86
Decreased neurotropism of nef long terminal repeat (nef/LTR)-deleted simian immunodeficiency virus. J Neurovirol (2003) 0.86
Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology (2008) 0.86
Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor. Nucleic Acids Res (2010) 0.86
Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS One (2012) 0.86
The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology (2013) 0.86
Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol (2012) 0.86
Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology (2009) 0.86
Disclosure decisions: HIV-positive persons coping with disease-related stressors. Qual Health Res (2011) 0.85
Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS (2010) 0.85
Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis (2013) 0.85
Mutation of C/EBPalpha predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen. Blood (2008) 0.85
Vaccines and vaccine strategies against HIV. Curr Drug Targets (2004) 0.85
In vitro dimerization of human immunodeficiency virus type 1 (HIV-1) spliced RNAs. RNA (2007) 0.84
Endogenous retroviruses and multiple sclerosis-new pieces to the puzzle. BMC Neurol (2013) 0.84
Efficient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector. Virology (2002) 0.84